Supporting Information

Immobilization of Manganese Dioxide Nanoparticles on Modified Poly 2,4-dichlorostyrene Microspheres: An Highly Efficient and Recyclable Catalyst for Borrowing Hydrogen Reactions

Ye Qiu,^{a,b} Yilin Zhang,^c Lu Jin,^a Le Pan,^a Guangming Du,^a Dongdong Ye,^b and Dawei

Wang*a,b

^a Chemical Engineering College, Xinjiang Agricultural University, Urumqi 830052, China. E-mail: wangdw@jiangnan.edu.cn ^b Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, China. ^c Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, West Virginia 26506, United States.

Table of contents

1. General methods and materials	S2
2. Synthesis of catalysts	S2
3. General procedure for the alkylation of acetophenone with alcohol	S4
4. Other characterization of catalysts	S4-S6
5. Hammett plot and mechanism studies	S6
6. Analytical data of the obtained compounds	S6-S19
7. NMR spectra of obtained compounds	S20-S72

1. General methods and materials:

All of the reactions dealing with air and/or moisture-sensitive reactions were carried out under an atmosphere of nitrogen using oven/flame-dried glassware and standard syringe/ Schlenk tube. Unless otherwise noted, all commercial reagents and solvents were obtained from the commercial provider and used without further purification. ¹H NMR and ¹³C NMR spectra were recorded on Bruker Advance III HD 400 or 101 MHz spectrometers. Chemical shifts were reported relative to internal tetramethylsilane ($\delta 0.00 \text{ ppm}$) or CDCl₃ ($\delta 7.26 \text{ ppm}$) for ¹H NMR and CDCl₃ ($\delta 77.0 \text{ ppm}$) for ¹³C NMR. Flash column chromatography was performed on 230-430 mesh silica gel. Analytical thin layer chromatography was performed with precoated glass baked plates (250μ) and visualized by fluorescence. HRMS were recorded on LTQ-FTUHRA spectrometer. The crystal structures were characterized with powder X-ray diffraction (XRD) on a Bruker D8 Advance X-ray diffractometer. TEM was recorded on a transmission electron microscope (JEM–2100, JEOL, Japan), operating at 200 kV. SEM image and EDS spectra was performed on a HITACHI S-4800 field-emission scanning electron microscope. XPS data were recorded with electron energy analyzer (ESCALAB 250Xi, Thermo Fisher Co, USA).

2. Synthesis of catalysts

The polyvinylpyrrolidone (1.400 g), azoisobutyronitrile (0.100 g), and isopropanol (80 mL) were separately weighed into a 250 ml Schlenk bottle, fully dissolved, and heated to 70 °C under nitrogen. fully dissolved, and heated to 70 °C under nitrogen. After completion of the reaction, 2,4-dichlorostyrene (10.0 g) was added, and polymerization was carried out for 24 hours while stirring at room temperature. The modified poly 2,4-dichlorostyrene microspheres (PDCS) were collected by centrifugation, washed three times with water and ethanol, sonicated, and finally freeze-dried for 12 hours.

The modified poly 2,4-dichlorostyrene microspheres (0.100 g), KMnO₄ (0.005 g), 20 mL of deionized water were added to a 100 mL round bottom flask and magnetically stirred for 10 minutes at room temperature to form a homogeneous solution. The solution was then transferred to a 40 mL teflon reactor and crystallized for 10 hours in an electrothermally heated constant temperature blast drying oven at 120 °C. After cooling to room temperature, remove the kettle, collected by centrifugation, and the impurities were removed by washing with deionized water for 3 to 4 times. Vacuum freeze-drying gave the product α -MnO₂@PDCS nanocatalyst.

The synthesis of other MnO₂ catalysts.

(α -MnO₂-PS) The polystyrene microspheres (0.100 g), KMnO₄ (0.005 g), 20 mL of deionized water were added to a 100 mL round bottom flask and magnetically stirred for 10 minutes at room temperature to form a homogeneous solution. The solution was then transferred to a 40 mL teflon reactor and crystallized for 10 hours in an electrothermally heated constant temperature blast drying oven at 120 °C. After cooling to room temperature, remove the kettle, collected by centrifugation, and the impurities were removed by washing with deionized water for 3 to 4 times. Vacuum freeze-drying gave the product α -MnO₂@PCS nanocatalyst.

(α -MnO₂-PCS) The poly 4-cyanostyrene microspheres (0.100 g), KMnO₄ (0.005 g), 20 mL of deionized water were added to a 100 mL round bottom flask and magnetically stirred for 10 minutes at room temperature to form a homogeneous solution. The solution was then transferred to a 40 mL teflon reactor and crystallized for 10 hours in an electrothermally heated constant temperature blast drying oven at 120 °C. After cooling to room temperature, remove the kettle, collected by centrifugation, and the impurities were removed by washing with deionized water for 3 to 4 times. Vacuum freeze-drying gave the product α -MnO₂@PCS nanocatalyst.

(α -MnO₂-PBS) The poly 4-bromostyrene microspheres (0.100 g), KMnO₄ (0.005 g), 20 mL of deionized water were added to a 100 mL round bottom flask and magnetically stirred for 10 minutes at room temperature to form a homogeneous solution. The solution was then transferred to a 40 mL teflon reactor and crystallized for 10 hours in an electrothermally heated constant temperature blast drying oven at 120 °C. After cooling to room temperature, remove the kettle, collected by centrifugation, and the impurities were removed by washing with deionized water for 3 to 4 times. Vacuum freeze-drying gave the product α -MnO₂@PCS nanocatalyst.

(α -MnO₂-PNS) The poly 4-nitrostyrene microspheres (0.100 g), KMnO₄ (0.005 g), 20 mL of deionized water were added to a 100 mL round bottom flask and magnetically stirred for 10 minutes at room temperature to form a homogeneous solution. The solution was then transferred to a 40 mL teflon reactor and crystallized for 10 hours in an electrothermally heated constant temperature blast drying oven at 120 °C. After cooling to room temperature, remove the kettle, collected by centrifugation, and the impurities were removed by washing with deionized water for 3 to 4 times. Vacuum freeze-drying gave the product α -MnO₂@PCS nanocatalyst.

3. General procedure for the alkylation of acetophenone with alcohol



To 20 mL Schlenk tube was added α -MnO₂@PDCS (15 mg), alcohol (1.2 mmol), acetophenone (1.0 mmol), NaOH (1.0 mmol) and toluene (2.5 mL). The mixture was heated under 120 °C for 12 h and TLC method was used to track and detect the reaction mixture. After the reaction, the solvent was removed by rotating evaporation, and the reaction mixture was separated by column chromatography with gradient elution method. The corresponding eluents were collected and combined with spin-dry solvents. (Petroleum ether /ethyl acetate (v/v = 40:1))

3.1 General procedure for cross-coupling of secondary and primary alcohols



To 20 mL Schlenk tube was added α -MnO₂@PDCS (15 mg), primary alcohol (1.2 mmol), Secondary alcohol (2.0 mmol), NaOH (1.0 mmol) and toluene (2.5 mL). The mixture was heated under 120 °C for 18 h and then cooled to room temperature. and TLC method was used to track and detect the reaction mixture. After the reaction, the solvent was removed by rotating evaporation, and the reaction mixture was separated by column chromatography with gradient elution method The corresponding eluents were collected and combined with spin-dry solvents. (Petroleum ether /ethyl acetate (v/v = 40:1)).

3.2 Representative procedure for the preparation of 6a



To 20 mL Schlenk tube was added α -MnO₂@PDCS (15 mg), alcohol (1.10 mmol), amine (0.50 mmol) and potassium *tert*-butoxide (0.75 mmol) and toluene (3.0 mL). The mixture was heated under 110 °C for 24 h and then cooled to room temperature. and TLC method was used to track and detect the reaction mixture. After the reaction, the solvent was removed by rotating evaporation, and the reaction mixture was separated by column chromatography with gradient elution method. The corresponding eluents were collected and combined with spin-dry solvents. (Petroleum ether /ethyl acetate (v/v = 60:1)).

4. Other characterizations of catalysts.



Fig.S1. TEM images of (a), (b) α -MnO₂-PDCS.





Fig.S2. SEM images of (a), (b) α -MnO₂-PS; (c), (d) α -MnO₂-PCS; (e), (f) α -MnO₂-PBS; (g), (h) α -MnO₂-PNS;

5. Hammett plot and mechanism studies.



Experimental procedure: To 20 mL Schlenk tube was added α -MnO₂@PDCS (15 mg), alcohol (1.2 mmol), acetophenone (1.0 mmol), NaOH (1.0 mmol) and toluene (2.5 mL). The mixture was heated under 120 °C for 1 h. After centrifugation and recovery the catalyst, the water mixture was diluted by water (5.0 mL) and extracted with EtOAc (3 x 10 mL). Next, the yield of product **3** was determined by GC.

R	Н	Me	OMe	F	CF ₃
Yield	12 %	19%	16%	7 %	5 %

6. Analytical data of the obtained compounds

(1) 1,3-diphenylpropan-1-one (3a)



¹H NMR (400 MHz, CDCl₃) δ 8.00 – 7.94 (m, 2H), 7.59 (t, *J* = 7.4 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 2H), 7.35 – 7.33 (m, 4H), 7.31 (t, *J* = 7.7 Hz, 1H), 3.41 (t, *J* = 7.7 Hz, 2H), 3.20 – 3.08 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.16, 141.42, 137.03, 132.99, 128.73, 128.54, 128.58, 128.07, 126.19, 40.53, 30.18.

(2) 1-phenyl-3-(p-tolyl)propan-1-one (3b)



¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 7.1 Hz, 2H), 7.59 – 7.52 (m, 1H), 7.48 (t, *J* = 7.6 Hz, 2H),

7.21(q, J = 8.1 Hz, 4H), 3.29– 3.16 (m, 2H), 3.11 – 3.04 (m, 2H), 2.41 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.43, 138.26, 136.89, 135.70, 133.11, 129.17, 128.58, 128.35, 127.99, 40.68, 29.81, 21.09.

(3) 3-(2-bromophenyl)-1-phenylpropan-1-one (3c)



¹H NMR (400 MHz, CDCl₃) δ 8.10 – 7.89 (m, 2H), 7.62 (t, *J* = 7.4 Hz, 2H), 7.51 (t, *J* = 7.6 Hz, 2H), 7.41 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.31 (td, *J* = 7.5, 1.1 Hz, 1H), 7.08 (td, *J* = 7.7, 1.7 Hz, 1H), 3.41 – 3.33 (m, 2H), 3.30 – 3.05 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.01, 140.68, 136.76, 133.09, 132.95, 130.87, 128.59, 128.07, 127.96, 127.72, 124.39, 38.56, 30.78.

(4) 3-phenyl-1-(*m*-tolyl)propan-1-one (3d)



¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, J = 8.9 Hz, 2H), 7.45 – 7.30 (m, 2H), 7.28 (m, 4H), 7.09 (t, J = 5.3 Hz, 1H), 3.28 (m, 2H), 3.16 – 2.99(m, 2H), 2.38 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.52, 141.43, 138.38, 136.87, 133.79, 128.99, 128.87, 128.49, 128.51, 126.08, 125.31, 40.49, 30.28, 21.43. **(5) 1-phenyl-3-(***o***-tolyl)propan-1-one (3e)**



¹H NMR (400 MHz, CDCl₃) δ 7.96 (dd, J = 8.3, 1.3 Hz, 2H), 7.71 – 7.50 (m, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.31 – 7.09 (m, 4H), 3.28 (dd, J = 9.0, 6.4 Hz, 2H), 3.06 (dd, J = 9.0, 6.7 Hz, 2H), 2.34 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.41, 139.37, 136.89, 135.97, 132.99, 130.41, 128.6, 128.56, 128.12, 126.26, 126.18, 39.06, 27.61, 19.42.

(6) 1-phenyl-3-(*m*-tolyl)propan-1-one (3f)



¹H NMR (400 MHz, CDCl₃) δ 7.99 – 7.94 (m, 2H), 7.64 – 7.52 (m, 1H), 7.48 (t, *J* = 7.6 Hz, 2H), 7.30 (t, *J* = 7.5 Hz, 1H), 7.03 (dd, *J* = 14.2, 9.4 Hz, 3H), 3.41 – 3.31 (m, 2H), 3.09 – 2.99 (m, 2H), 2.41 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.40, 141.31, 138.08, 136.87, 133.00, 129.32, 128.69, 128.53, 128.11, 127.08, 125.56, 40.63, 29.98, 21.54.

(7) 3-(4-chlorophenyl)-1-phenylpropan-1-one (3g)



¹H NMR (400 MHz, CDCl3) δ 8.03 – 7.90 (m, 2H), 7.64 – 7.54 (m, 1H), 7.49 – 7.38 (m, 2H), 7.33 – 7.21(m, 2H), 7.25 – 7.09 (m, 2H), 3.29 (t, *J* = 7.5 Hz, 2H), 3.11 (t, *J* = 7.5 Hz, 2H). ¹³C NMR (101 MHz, CDCl3) δ 198.87, 139.80, 136.84, 133.21, 131.93, 130.41, 129.95, 128.73, 127.98, 40.21, 29.39. **(8) 3-(4-methoxyphenyl)-1-phenylpropan-1-one (3h)**



¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 7.5 Hz, 2H), 7.63 (t, J = 7.4 Hz, 1H), 7.53 (t, J = 7.6 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 3.79 (s, 3H), 3.38 (t, J = 7.7 Hz, 2H), 3.11 (t, J = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.50, 159.98, 137.00, 133.45, 133.11, 129.43, 128.70, 127.99, 114.01, 55.27, 40.84, 29.28.

(9) 1-(4-chlorophenyl)-3-(4-methoxyphenyl)propan-1-one (3i)



¹H NMR (400 MHz, CDCl₃) δ 7.98 – 7.80 (m, 2H), 7.53 – 7.37 (m, 2H), 7.21 – 7.18 (m, 2H), 6.93 – 6.79 (m, 2H), 3.76 (s, 3H), 3.31 (t, *J* = 7.6 Hz, 2H), 2.97 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 198.04, 158.13, 139.52, 135.31, 133.11, 129.52, 129.41, 128.87, 114.05, 55.35, 40.73, 29.18. **(10) 3-(4-methoxyphenyl)-1-(***m***-tolyl)propan-1-one (3j)**



¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 10.2 Hz, 2H), 7.39–7.29 (m, 2H), 7.17 (d, J = 8.6 Hz, 2H), 6.93(d, J = 8.6 Hz, 2H), 3.87 (s, 3H), 3.34 (t, J = 7.7 Hz, 2H), 3.11 (t, J = 7.6 Hz, 2H), 2.50 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.64, 158.11, 138.43, 137.08, 133.79, 133.38, 129.39, 128.59, 128.47, 125.27, 114.02, 55.31, 40.82, 29.44, 21.41.

(11) 3-(4-chlorophenyl)-1-(3-methoxyphenyl)propan-1-one (3k)



¹H NMR (400 MHz, CDCl₃) δ 7.61 – 7.43 (m, 2H), 7.41 (t, *J* = 7.9 Hz, 1H), 7.33 (dd, *J* = 8.1, 2.7 Hz, 2H), 7.16 (s, 2H), 7.09 (dd, *J* = 8.2, 2.6 Hz, 1H), 3.01 (s, 3H), 3.34 (t, *J* = 7.5 Hz, 2H), 2.99 (t, *J* = 7.5 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 198.73, 159.88, 139.78, 138.21, 131.89, 129.79, 129.71, 128.65, 120.58, 119.70, 112.40, 55.50, 40.27, 29.50.

(12) 3-(4-bromophenyl)-1-(3-methoxyphenyl)propan-1-one (3l)



¹H NMR (400 MHz, CDCl₃) δ 7.61– 7.50 (m, 2H), 7.48 – 7.38 (m, 2H), 7.41 – 7.28 (m, 1H), 7.20 – 7.13 (m, 3H), 3.90 (s, 3H), 3.28 – 3.15 (m, 2H), 3.11 (dd, *J* = 9.5, 5.5 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 198.63, 159.98, 140.31, 138.25, 131.64, 130.31, 129.73, 120.70, 119.98, 119.59, 112.41, 55.50, 40.21, 29.48.

(13) 3-(4-methoxyphenyl)-1-(o-tolyl)propan-1-one (3m)



¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, *J* = 7.0 Hz, 1H), 7.42 (t, *J* = 7.5 Hz, 1H), 7.31 – 7.18 (m, 2H), 7.15 (d, *J* = 8.6 Hz, 2H), 6.91 (d, *J* = 8.6 Hz, 2H), 3.74 (s, 3H), 3.28 (t, *J* = 7.6 Hz, 2H), 2.99 (t, *J* = 7.6 Hz, 2H), 2.52 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 203.57, 157.99, 138.03, 138.06, 133.34, 131.87, 131.23, 129.40, 128.37, 125.71, 114.00, 55.34, 43.47, 29.54, 21.19.

(14) 3-phenyl-1-(o-tolyl)propan-1-one (3n)



¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 7.5 Hz, 1H), 7.41 (t, *J* = 7.4 Hz, 1H), 7.33 (t, *J* = 7.4 Hz, 2H), 7.18 (dd, *J* = 17.6, 6.7 Hz, 5H), 3.17 (t, *J* = 7.6 Hz, 2H), 2.99 (t, *J* = 7.6 Hz, 2H), 2.51 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 203.38, 141.31, 138.29, 137.98, 131.98, 131.31, 128.60, 128.52, 128.38, 126.09, 125.68, 43.31, 30.40, 21.33.

(15) 3-(4-methoxyphenyl)-1-(p-tolyl)propan-1-one (30)



¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 8.2 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.18 (d, *J* = 8.6 Hz, 2H), 6.93 (d, *J* = 8.6 Hz, 2H), 3.86 (s, 3H), 3.33 (t, *J* = 7.7 Hz, 2H), 2.98 (t, *J* = 7.7 Hz, 2H), 2.53 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 198.98, 158.13, 143.87, 134.45, 133.50, 129.37, 129.29, 128.27, 114.00, 55.31, 40.56, 29.38, 21.70.

(16) 1-(4-methoxyphenyl)-3-(p-tolyl)propan-1-one (3p)



¹H NMR (400 MHz, CDCl₃) δ 7.99 – 7.87 (m, 2H), 7.23 (q, J = 8.1 Hz, 4H), 7.05 – 6.87 (m, 2H), 3.91 (s, 3H), 3.30 (dd, J = 8.7, 6.8 Hz, 2H), 3.11 – 3.04 (m, 2H), 2.35 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 198.03, 163.53, 138.30, 135.51, 130.40, 129.98, 129.29, 128.47, 113.83, 55.53, 40.29, 30.01, 21.10. (17) 3-phenyl-1-(*p*-tolyl)propan-1-one (3q)



¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, J = 8.2 Hz, 2H), 7.41 – 7.29 (m, 2H), 7.27 – 7.19 (m, 4H), 7.21 (d, J = 7.0 Hz, 1H), 3.43 – 3.31 (m, 2H), 3.21 – 3.11 (m, 2H), 2.47 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 198.89, 143.92, 141.47, 134.50, 129.37, 128.48, 128.477, 128.25, 126.18, 40.41, 30.33, 21.71. **(18) 1-(4-methoxyphenyl)-3-phenylpropan-1-one (3r)**



¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 8.9 Hz, 2H), 7.40 (dt, J = 14.6, 7.2 Hz, 4H), 7.21 (d, J = 7.2 Hz, 1H), 7.00 (d, J = 8.9 Hz, 2H), 3.94 (s, 3H), 3.40 (m, 2H), 3.15 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 197.79, 163.52, 141.56, 130.40, 128.98, 128.61, 128.51, 126.09, 113.83, 55.51, 40.09, 30.41. **(19) 3-(4-methoxyphenyl)-1-phenylpropan-1-one (3s)**



¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 7.5 Hz, 2H), 7.61 (t, *J* = 7.4 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.19 (d, *J* = 8.5 Hz, 2H), 6.91 (d, *J* = 8.6 Hz, 2H), 3.79 (s, 3H), 3.28 (t, *J* = 7.7 Hz, 2H), 3.01 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.37, 157.98, 136.97, 133.29, 132.97, 129.34, 128.59, 127.98, 114.02, 55.27, 40.63, 29.27.

(20) 1-(4-methoxyphenyl)-3-(m-tolyl)propan-1-one (3t)



¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, *J* = 8.9 Hz, 2H), 7.31 (t, *J* = 7.5 Hz, 1H), 7.14 – 7.02 (m, 3H), 7.00(d, *J* = 8.9 Hz, 2H), 3.93 (s, 3H), 3.41 – 3.27 (m, 2H), 3.20 – 3.01 (m, 2H), 2.43 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 197.79, 163.54, 141.40, 138.14, 130.42, 130.14, 129.34, 128.53, 126.92, 125.53, 113.82, 55.51, 40.23, 30.40, 21.53.

(21) 1-(3-methoxyphenyl)-3-phenylpropan-1-one (3u)



¹H NMR (400 MHz, CDCl₃) δ 7.58 – 7.47 (m, 2H), 7.40 – 7.20 (m, 6H), 7.13 (dd, J = 8.2, 2.6 Hz, 1H), 3.93 (s, 3H), 3.41 (t, J = 7.7 Hz, 2H), 3.09 (t, J = 7.7 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.11, 159.97, 141.28, 138.37, 129.57, 128.61, 128.54, 126.21, 120.75, 119.63, 112.41, 55.50, 40.61, 30.32. (22) 1-(4-methoxyphenyl)-3-(*m*-tolyl)propan-1-one (3v)



¹H NMR (400 MHz, CDCl₃) δ 8.03 – 7.89 (m, 2H), 7.18 (t, *J* = 7.5 Hz, 1H), 7.03 (dd, *J* = 14.1, 9.3 Hz, 3H), 6.97 – 6.87 (m, 2H), 3.91 (s, 3H), 3.31 (dd, *J* = 8.8, 6.8 Hz, 2H), 3.05 – 2.97 (m, 2H), 2.35 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 197.91, 163.50, 141.47, 138.11, 130.40, 130.11, 129.31, 128.36, 126.91, 125.47, 113.81, 55.51, 40.27, 30.28, 21.45.

(23) 3-(3-bromophenyl)-1-(4-methoxyphenyl)propan-1-one (3w)



¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, J = 8.9 Hz, 1H), 7.50 (s, 1H), 7.41 (d, J = 7.3 Hz, 1H), 7.30 – 7.17 (m, 1H), 6.90 (d, J = 8.9 Hz, 1H), 3.84 (s, 2H), 3.31 (t, J = 7.7 Hz, 1H), 3.13 (t, J = 7.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 197.21, 163.63, 143.89, 131.98, 131.63, 130.27, 130.15, 129.25, 127.27, 122.56, 113.84, 55.52, 39.71, 29.91.

(24) 3-(3,5-dimethoxyphenyl)-1-phenylpropan-1-one (3x)



¹H NMR (400 MHz, CDCl₃) δ 8.03 – 7.87 (m, 2H), 7.64 – 7.52 (m, 1H), 7.43 (dd, *J* = 10.5, 4.7 Hz, 2H), 6.48 (d, *J* = 2.3 Hz, 2H), 6.33 (t, *J* = 2.2 Hz, 1H), 3.85 (s, 6H), 3.40 (dd, *J* = 8.5, 6.9 Hz, 2H), 3.11 – 3.05 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.23, 161.08, 143.83, 136.91, 133.17, 128.72, 128.15, 106.58, 98.16, 55.31, 4033, 30.52.

(25) 3-(3-bromophenyl)-1-(3-methoxyphenyl)propan-1-one (3y)



¹H NMR (400 MHz, CDCl₃) δ 7.63 – 7.52(m, 2H), 7.43 (dd, *J* = 14.3, 6.5 Hz, 2H), 7.26 (t, *J* = 8.1 Hz, 2H), 7.15 (ddd, *J* = 19.9, 11.8, 6.7 Hz, 2H), 3.91 (s, 3H), 3.28 (t, *J* = 7.6 Hz, 2H), 3.11 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 198.53, 159.97, 143.73, 138.21, 131.57, 130.13, 129.73, 129.31, 127.27, 122.61, 120.71, 119.73, 112.40, 55.51, 40.17, 29.83.

(26) 3-(4-chlorophenyl)-1-(4-methoxyphenyl)propan-1-one (3z)



¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 8.9 Hz, 2H), 7.34 (d, *J* = 8.5 Hz, 2H), 7.27 (d, *J* = 8.4 Hz, 2H), 7.03 (d, *J* = 8.9 Hz, 2H), 3.93 (s, 3H), 3.33 (t, *J* = 7.6 Hz, 2H), 2.98 (t, *J* = 7.6 Hz, 2H). ¹³C NMR

(101 MHz, CDCl₃) δ 197.55, 163.61, 140.00, 131.93, 130.42, 130.27, 129.93, 128.42, 113.81, 55.53, 39.84, 29.62

(27) 1-(4-bromophenyl)-3-(4-methoxyphenyl)propan-1-one (3aa)



¹H NMR (400 MHz, CDCl₃) δ 8.03 (dd, J = 20.0, 7.7 Hz, 2H), 7.49 – 7.29 (m, 2H), 7.20 – 7.11 (m, 2H), 6.93 (t, J = 6.2 Hz, 2H), 3.87 (s, 3H), 3.41 – 3.28 (m, 2H), 3.11 – 3.08 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.43, 158.11, 137.01, 133.43, 133.12, 129.42, 128.67, 128.11, 114.02, 55.31, 40.63, 29.40.

(28) 1-(3-methoxyphenyl)-3-phenylpropan-1-one (3ab)



¹H NMR (400 MHz, CDCl₃) δ 7.63 – 7.47 (m, 2H), 7.40 – 7.17 (m, 6H), 7.12 (dd, *J* = 8.2, 2.6 Hz, 1H), 3.93 (s, 3H), 3.40 (t, *J* = 7.7 Hz, 2H), 2.97 (t, *J* = 7.7 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.11, 159.97, 141.38, 138.27, 129.59, 128.61, 128.53, 126.22, 120.75, 119.63, 112.41, 55.52, 40.63, 30.27. (**29)** 1-(3-methoxyphenyl)-3-(*p*-tolyl)propan-1-one (3ac)



¹H NMR (400 MHz, CDCl₃) δ 7.63 (dd, J = 13.4, 5.1 Hz, 2H), 7.42 (t, J = 7.9 Hz, 1H), 7.31 – 7.15 (m, 5H), 3.93 (s, 3H), 3.41 (t, J = 7.7 Hz, 2H), 3.09 – 3.11 (m, 2H), 2.39 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.17, 159.94, 138.41, 138.30, 135.58, 129.56, 129.33, 128.40, 120.68, 119.62, 112.41, 55.50, 40.78, 29.88, 21.08.

(30) 3-phenyl-1-(m-tolyl)propan-1-one (3ad)



¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 8.9 Hz, 2H), 7.45 – 7.32 (m, 2H), 7.28 (m, 4H), 7.20 (t, J = 5.3 Hz, 1H), 3.35 (m, 2H), 3.13 – 3.04 (m, 2H), 2.38 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.53, 141.42, 138.38, 137.00, 133.90, 129.11, 128.59, 128.59, 128.53, 126.18, 125.31, 40.69, 30.27, 21.43. **(31) 1-(4-methoxyphenyl)-3-(thiophen-2-yl)propan-1-one (3ae)**



¹H NMR (400 MHz, CDCl₃) δ 8.03 – 7.92 (m, 2H), 7.15 (dd, J = 5.1, 1.2 Hz, 1H), 6.99 – 6.92 (m, 3H), 6.88 (dd, J = 3.3, 0.7 Hz, 1H), 3.88 (s, 3H), 3.32 (dt, J = 5.6, 2.7 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 197.09, 163.63, 144.17, 130.38, 129.95, 126.92, 124.70, 123.41, 113.83, 55.52, 40.24, 24.50.

(32) 1-phenyl-3-(thiophen-2-yl)propan-1-one (3af)



¹H NMR (400 MHz, CDCl₃) δ 8.00 – 7.94 (m, 2H), 7.71 – 7.60 (m, 1H), 7.53 (t, *J* = 7.6 Hz, 2H), 7.21 (dd, *J* = 5.1, 1.2 Hz, 1H), 7.02 (dd, *J* = 5.1, 3.4 Hz, 1H), 6.95 (dd, *J* = 3.4, 0.9 Hz, 1H), 3.38 – 3.35 (m, 2H), 3.33 – 3.26 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 198.51, 143.89, 136.81, 133.23, 128.70, 128.11, 126.92, 124.74, 123.36, 40.60, 24.27.

(33) 3-(4-methoxyphenyl)-1-phenylpropan-1-one (3ag)



¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, *J* = 7.5 Hz, 2H), 7.63 (t, *J* = 7.4 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.27 (d, *J* = 8.5 Hz, 2H), 6.93 (d, *J* = 8.6 Hz, 2H), 3.87 (s, 3H), 3.35 (t, *J* = 7.7 Hz, 2H), 3.11 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.46, 158.10, 136.97, 133.42, 133.13, 129.43, 128.58, 128.11, 114.02, 55.28, 40.79, 29.28.

(34) 1-phenyl-3-(p-tolyl)propan-1-one (3ah)



¹H NMR (400 MHz, CDCl₃) δ 8.03 – 7.94 (m, 2H), 7.69 – 7.61 (m, 1H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.18 (q, *J* = 8.1 Hz, 4H), 3.43 – 3.20(m, 2H), 3.17 – 3.04(m, 2H), 2.41 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.42, 138.27, 136.95, 135.68, 133.12, 129.28, 128.59, 128.33, 128.13, 40.71, 29.75, 21.19.

(35) 3-([1,1'-biphenyl]-4-yl)-1-phenylpropan-1-one (3ai)



¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 7.3 Hz, 2H), 7.72 – 7.54 (m, 5H), 7.53 (dd, *J* = 17.5, 7.9 Hz, 4H), 7.45 – 7.30 (m, 3H), 3.43 (t, *J* = 7.6 Hz, 2H), 3.21 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.19, 141.17, 140.52, 139.21, 136.97, 133.20, 128.98, 128.84, 128.71, 128.18, 127.37, 127.21, 127.18, 40.47, 29.82.

(36) 1-(4-chlorophenyl)-3-phenylpropan-1-one (3aj)



¹H NMR (400 MHz, CDCl₃) δ 8.00 – 7.93 (m, 2H), 7.52 – 7.46 (m, 2H), 7.40 – 7.37 (m, 2H), 7.31 – 7.19 (m, 3H), 3.27 (t, *J* = 7.7 Hz, 2H), 3.11 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 198.08, 141.21, 139.48, 135.17, 129.52, 129.01, 128.63, 128.38, 126.31, 40.47, 30.11.

(37) 1-(naphthalen-2-yl)-3-phenylpropan-1-one (3ak)



¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 1H), 8.15 (d, *J* = 8.6 Hz, 1H), 8.00 – 7.93 (m, 2H), 7.74– 7.59 (m, 1H), 7.42 (dd, *J* = 4.7, 2.5 Hz, 2H), 7.38 – 7.27 (m, 4H), 3.52 (t, *J* = 7.8 Hz, 2H), 3.35 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 199.21, 141.53, 135.71, 134.33, 132.59, 129.83, 129.71, 129.23, 128.70, 128.61, 128.51, 127.93, 126.91, 126.33, 124.01, 40.63, 30.42.

(38) 1-(4-chlorophenyl)-3-(4-methoxyphenyl)propan-1-one (3al)



¹H NMR (400 MHz, CDCl₃) δ 7.97 – 7.84 (m, 2H), 7.52 – 7.45 (m, 2H), 7.27 – 7.09 (m, 2H), 6.92 – 6.83 (m, 2H), 3.87 (s, 3H), 3.33 (t, *J* = 7.6 Hz, 2H), 3.28 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 198.21, 158.11, 139.53, 135.30, 133.15, 129.52, 129.41, 128.97, 114.08, 55.31, 40.73, 29.34. **(39) 1-(4-chlorophenyl)-3-(***m***-tolyl)propan-1-one (3am)**



¹H NMR (400 MHz, CDCl₃) δ 8.02 – 7.90 (m, 2H), 7.48 – 7.39 (m, 2H), 7.23 (t, *J* = 7.5 Hz, 1H), 7.09 (dd, *J* = 13.6, 5.8 Hz, 3H), 3.41 – 3.31 (m, 2H), 3.08 – 3.02 (m, 2H), 2.47 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 198.05, 141.12, 139.53, 138.23, 135.31, 129.60, 129.33, 128.99, 128.65, 127.12, 125.53, 40.60, 30.17, 21.54.

(40) 1-(4-methoxyphenyl)-3-(o-tolyl)propan-1-one (3an)



¹H NMR (400 MHz, CDCl₃) δ 8.00 – 7.96 (m, 2H), 7.31 – 7.20 (m, 4H), 7.09 – 6.97 (m, 2H), 3.94 (s, 3H), 3.40 – 3.23 (m, 2H), 3.09 – 2.98 (m, 2H), 2.47 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 198.01, 163.57, 139.63, 135.98, 130.41, 130.40, 139.98, 128.84, 126.28, 126.25, 113.81, 55.51, 38.87, 27.82, 19.43.

(41) 1-benzyl-2-phenyl-1H-benzo[d]imidazole (6a).



¹H NMR (400 MHz, CDCl₃) δ 7.91 (d, J = 8.0 Hz, 1H), 7.75 – 7.70 (m, 2H), 7.53 – 7.45 (m, 3H), 7.38 – 7.31 (m, 4H), 7.24 (td, J = 7.8, 1.3 Hz, 2H), 7.17 – 7.10 (m, 2H), 5.48 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ =154.21, 143.26, 136.50, 136.21, 130.22, 130.02, 129.43, 129.19, 128.82, 127.79, 126.09, 123.11, 122.68, 120.11, 110.65, 48.49.

(42) 1-(4-methylbenzyl)-2-(p-tolyl)-1H-benzo[d]imidazole (6b)



¹H NMR (400 MHz, CDCl₃): δ = 8.01 (d, *J* = 8.0 Hz, 1H), 7.71 (d, *J* = 8.1 Hz, 2H), 7.40 – 7.32 (m, 3H), 7.29–7.22 (m, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 5.51 (s, 2H), 2.51 (s, 3H), 2.42 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ = 154.43, 143.32, 140.15, 137.56, 136.23, 133.41, 129.68, 129.51, 129.19, 127.17, 125.88, 122.81, 122.63, 119.90, 110.60, 48.32, 21.50, 21.20.

(43) 1-(2-methylbenzyl)-2-(o-tolyl)-1H-benzo[d]imidazole (6c).



¹H NMR (400 MHz, CDCl₃): $\delta = 8.01$ (d, J = 8.0 Hz, 1H), 7.50– 7.47 (m, 4H), 7.39– 7.20 (m, 5H), 7.16 (td, J = 8.0, 2.5 Hz, 1H), 6.80 (d, J = 7.7 Hz, 1H), 5.29 (s, 2H), 2.38 (s, 3H), 2.28 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): $\delta = 154.01$, 143.32, 138.46, 135.25, 135.02, 134.09, 131.02, 130.73, 130.49, 129.98, 129.93, 127.67, 126.46, 126.21, 125.73, 122.97, 122.49, 120.16, 110.74, 45.92, 19.89, 19.13. **(44) 2-(thiophen-2-yl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole (6d).**



¹H NMR (400 MHz, DMSO): δ = 7.88 (d, *J* = 5.1 Hz, 1H), 7.80 – 7.72 (m, 3H), 7.45 (d, *J* = 5.0 Hz, 1H), 7.33 (ddd, *J* = 13.1, 7.6, 5.6 Hz, 3H), 7.08 (d, *J* = 3.3 Hz, 1H), 7.10 – 6.98 (m, 1H), 5.97 (s, 2H). ¹³C NMR (101 MHz, DMSO): δ = 147.23, 143.93, 139.90, 136.40, 132.48, 130.18, 128.90, 128.41, 127.59, 126.60, 126.48, 123.40, 123.11, 119.53, 111.33, 43.62.

(45) 1-(3-chlorobenzyl)-2-(3-chlorophenyl)-1H-benzo[d]imidazole (6e).



¹H NMR (400 MHz, CDCl₃): δ = 7.91 (d, *J* = 8.0 Hz, 1H), 7.81 (t, *J* = 1.8 Hz, 1H), 7.60 – 7.53 (m, 2H), 7.50 – 7.42 (m, 2H), 7.39 – 7.32 (m, 3H), 7.31 – 7.30 (m, 1H), 7.22 (s, 1H), 7.01 (d, *J* = 7.1 Hz, 1H), 5.50 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ = 152.58, 143.20, 138.27, 136.00, 135.31, 135.08, 131.76, 130.52, 130.21, 130.11, 129.58, 128.39, 127.14, 126.31, 124.19, 123.73, 123.20, 120.43, 110.38, 48.00.

(46) 1-(4-chlorobenzyl)-2-(4-chlorophenyl)-1H-benzo[d]imidazole (6f).



¹H NMR (400 MHz, DMSO): δ = 7.81 – 7.75 (m, 3H), 7.59 (d, *J* = 8.4 Hz, 2H), 7.58 – 7.43 (m, 1H), 7.43 (d, *J* = 8.4 Hz, 2H), 7.35 – 7.28 (m, 2H), 7.08 (d, *J* = 8.4 Hz, 2H), 5.69 (s, 2H). ¹³C NMR (101 MHz, DMSO): δ = 152.58, 143.17, 138.30, 136.41, 136.32, 135.31, 132.68, 131.63, 131.31, 130.28, 129.49, 129.27, 128.51, 123.50, 122.96, 120.01, 111.61, 47.40.

(47) 1-(2,5-difluorobenzyl)-2-(2,5-difluorophenyl)-1H-benzo[d]imidazole (6g).



¹H NMR (400 MHz, CDCl₃): δ = 7.91 (d, *J* = 7.2 Hz, 1H), 7.45 – 7.33 (m, 4H), 7.30 – 7.21 (m, 2H), 7.10 (td, *J* = 9.9, 4.4 Hz, 1H), 7.08 – 6.93 (m, 1H), 6.57 – 6.51 (m, 1H), 5.42 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ = 158.80, 156.13, 148.02, 143.31, 135.20, 124.60, 123.91, 123.17, 120.55, 119.95, 117.49, 116.78, 116.21, 115.14, 114.90, 110.42, 42.24.

(48) 1-(2-chlorobenzyl)-2-(2-chlorophenyl)-1H-benzo[d]imidazole (6h).



¹H NMR (400 MHz, CDCl₃): δ = 7.95 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.53 - 7.41 (m,

2H), 7.38 – 7.29 (m, 4H), 7.26 – 7.08 (m, 2H), 7.07 (t, J = 7.2 Hz, 1H), 6.70 (d, J = 7.6 Hz, 1H), 5.52 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ = 151.58, 143.16, 134.86, 134.48, 133.41, 132.45, 132.20, 131.49, 1300.00, 129.79, 129.68, 129.10, 127.89, 127.21, 127.01, 123.47, 122.79, 120.46, 110.58, 45.77.
(49) 1-(4-fluorobenzyl)-2-(4-fluorophenyl)-5-methyl-1H-benzo[d]imidazole (6i).



¹H NMR (400 MHz, CDCl₃): δ = 7.82– 7.58 (m, 3H), 7.28 – 7.11(m, 3H), 7.09 (s, 1H), 7.10 – 7.00 (m, 4H), 5.40 (s, 2H), 2.58 (d, *J* = 20.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ = 163.76 163.58, 161.11, 153.07, 152.67, 143.50, 141.27, 136.19, 134.11, 133.4,2 132.68, 132.09, 131.19, 127.58, 126.43,124.80, 124.58, 119.90, 119.63, 116.10, 110.21, 109.94, 47.59, 21.90, 21.62.

(50) 1-(4-(tert-butyl)benzyl)-2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole (6j).



*t*Bu′

¹H NMR (400 MHz, CDCl₃) δ = 7.92 (d, *J* = 8.0 Hz, 1H), 7.78 (dt, *J* = 8.4, 2.0 Hz 2H), 7.58 (dt, *J* = 8.8, 2.0 Hz, 2H), 7.43 – 7.20 (m, 3H), 7.28 – 7.17 (m, 2H), 7.14 (d, *J* = 8.4 Hz, 2H), 5.56 (s, 2H), 1.43 (s, 9H), 1.41 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ = 154.37, 153.15, 150.71, 143.36, 136.20, 133.53, 129.10, 127.30, 126.00, 125.74, 122.82, 122.57, 119.90, 110.65, 48.20, 34.91, 34.60, 31.40,31.39. **(51) 1-(3,4-difluorobenzyl)-2-(3,4-difluorophenyl)-1H-benzo[d]imidazole (6k).**



¹H NMR (400 MHz, CDCl₃): δ = 7.93 (d, *J* = 8.0 Hz, 1H), 7.65 – 7.48 (m, 1H), 7.43 – 7.30 (m, 4H), 7.28– 7.01 (m, 2H), 6.98 – 6.90 (m, 1H), 6.89 – 6.84 (m, 1H), 5.47 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ = 152.11, 150.48, 149.25, 142.70, 135.70, 133.15 – 132.57 (m), 126.69, 125.58, 124.01, 123.53, 121.95, 120.30, 119.26, 118.71, 118.05, 117.23, 115.92 – 115.17 (m), 115.30, 115.11, 110.27, 47.45.

(52) 1-(3,5-difluorobenzyl)-2-(3,5-difluorophenyl)-1H-benzo[d]imidazole (6l).



¹H NMR (400 MHz, CDCl₃): δ = 7.91 (d, *J* = 7.8 Hz, 1H), 7.43 – 7.34 (m, 2H), 7.27 – 7.10 (m, 3H), 7.00 (tt, *J* = 8.7, 2.3 Hz, 1H), 6.83 (tt, *J* = 8.7, 2.2 Hz, 1H), 6.71 – 6.53 (m, 2H), 5.40 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ = 163.41, 151.37, 143.03, 140.01, 135.98, 132.79, 124.09, 123.57, 120.56, 112.28, 110. 17, 109.05, 105.70, 104.13, 103.86, 103.60, 47.78

(53) 1-(4-chlorobenzyl)-2-(4-chlorophenyl)-5-methyl-1H-benzo[d]imidazole(6m)



¹H NMR (400 MHz, CDCl₃): δ = 7.80– 7.57 (m, 3H), 7.46 (d, *J* = 8.3 Hz, 2H), 7.33 – 7.19 (m, 2H), 7.20 – 6.95 (m, 4H), 5.40 (d, *J* = 6.8 Hz, 2H), 2.51 (dd, *J* = 21.1, 9.6 Hz, 3H). ¹³C NMR (101MHz, CDCl₃): δ = 152.80, 152.41, 143.50, 141.30, 136.33, 136.20, 136.07, 134.90, 134.87, 134.12, 133.80, 133.68, 132.80, 132.76, 130.42, 130.29, 129.43, 129.38, 129.11, 128.60, 127.33, 127.29, 125.03, 124.72, 119.96, 119.71, 110.20, 109.78, 47.83, 47.59, 21.93, 21.63.

(54) 1-(4-ethylbenzyl)-2-(4-ethylphenyl)-5-methyl-1H-benzo[d]imidazole (6n)



¹H NMR (400 MHz, CDCl₃) δ = 7.87 – 7.65 (m, 3H), 7.38 (dd, *J* = 8.2, 4.2 Hz, 2H), 7.30 – 7.18 (m, 3H), 7.15–7.05(m, 3H), 5.47 (s, 2H), 2.80 – 2.57 (m, 4H), 2.48 (d, *J* = 27.4 Hz, 3H), 1.35 – 1.19 (m, 6H). ¹³CNMR (101MHz, CDCl₃): δ = 154.27, 153.93, 146.19, 146.15, 143.75, 143.73, 143.66, 141.49, 136.58, 134.39, 134.03, 133.97, 132.89, 132.25, 129.31, 129.29, 128.56, 128.58, 128.32, 128.31, 127.67, 126.11, 126.02, 124.38, 124.23, 119.70, 119.42, 110.41, 110.18, 48.27, 48.13,28.81, 28.57, 21.93, 21.73, 15.52, 15.43.

(55) 5-methyl-1-(4-methylbenzyl)-2-(p-tolyl)-1H-benzo[d]imidazole (60)



¹H NMR (400 MHz, CDCl₃): δ = 7.88 – 7.76 (m, 1H), 7.71 – 7.67 (m, 2H), 7.30 (dd, *J* = 7.9, 3.8 Hz,

2H), 7.20– 7.00 (m, 6H), 5.41 (s, 2H), 2.52 (d, J = 31.6 Hz, 3H), 2.49 (s, 3H), 2.41 (d, J = 4.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): $\delta = 154.30$, 153.90, 143.71, 141.50, 139.90, 139.87, 137.28, 137.38, 136.53, 134.38, 133.77, 133.78, 132.85, 132.19, 129.73, 129.71, 129.53, 129.54, 129.24, 129.18, 127.52, 125.94, 125.81, 124.35, 124.27, 119.60, 119.45, 110.38, 110.17, 48.18, 48.09, 21.86, 21.69, 21.48, 21.13.



S20













210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)









S30











S35




S37

















S45









S49













210 200 190 180 170 180 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10







7, 20 2, 20





-48.40













5.00 1.00





-47.91































